In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Otsuka buys PDL's IV Busulfex for $200mm

Executive Summary

In line with its planned asset sales and reorganization, PDL BioPharma (treatments for life-threatening diseases) has sold Otsuka Pharmaceutical Co. all rights to its IV Busulfex (busulfan) oncology product for $200mm cash.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies